Novo reports 25.4% mean weight loss among early CagriSema responders
- Early responders, defined as at least 5% weight loss by week 8, had mean observed weight loss of 25.4% at week 68, versus 17.8% for delayed responders.
- Women were more likely to be early than delayed responders: 71.8% versus 59.5%.
- At week 68, 73.1% on CagriSema reported meaningful physical-function improvement versus 49.1% on placebo.
- CagriSema is investigational; Novo filed a US New Drug Application in December 2025, with an FDA decision expected in Q4 2026.
Weight-loss response
Two post hoc analyses of the phase 3 REDEFINE 1 trial of investigational CagriSema, a fixed-dose combination of cagrilintide and semaglutide, were presented at ObesityWeek 2026. Among participants receiving 2.4 mg/2.4 mg, 67.8% were early responders, defined as achieving at least 5% weight loss by week 8. Their mean observed weight loss at week 68 was 25.4%, compared with 17.8% among delayed responders, who had lost less than 5% by week 8. These on-treatment findings are post hoc and hypothesis-generating.
Patient-reported function and safety
At week 68, 73.1% of participants receiving CagriSema reported a meaningful improvement in physical function, compared with 49.1% receiving placebo. Meaningful improvement in psychosocial function was reported by 69.0% and 42.1%, respectively. The efficacy estimand assumes participants adhered to treatment.
Adverse events led to discontinuation in 5.9% of CagriSema participants and 3.5% of placebo participants. Gastrointestinal events occurred in 79.6% and 39.9%, respectively, and were mostly transient and mild to moderate. Novo filed a US New Drug Application for weight management in December 2025; an FDA decision is expected in Q4 2026. CagriSema is not approved in the United States.
Source: Novo Nordisk